Form 4: Adaptive Biotechnologies Director Michelle Griffin Reports Stock Transactions

Sentiment:

SEC Form 4


Director Michelle Griffin reports acquisition and disposal of Adaptive Biotechnologies stock and stock options under a pre-arranged trading plan.

Summary

  • On March 4, 2025, Michelle Griffin, a director of Adaptive Biotechnologies Corp, acquired 15,394 shares of common stock at $0.
  • On March 6, 2025, Griffin disposed of 15,664 shares of common stock at a weighted-average price of $7.94, with individual sales ranging from $7.64 to $8.21.
  • Following these transactions, Griffin beneficially owns 51,685 shares of common stock.
  • Griffin also acquired 23,726 stock options with an exercise price of $8.12, vesting monthly over one year from March 4, 2025, and expiring on March 4, 2035.
  • These transactions were executed under a Rule 10b5-1 trading plan adopted on November 18, 2024.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by a company director. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

This Form 4 filing is a routine disclosure of stock transactions by a company insider, providing transparency to investors regarding the trading activities of key personnel. It is common practice for directors and officers to utilize 10b5-1 trading plans to avoid accusations of insider trading.

Stakeholder Impact

  • Shareholders are informed about the stock transactions of a key company director, providing insight into insider activity.
  • The transactions may have a minor impact on the stock price, depending on market perception.

Key Dates

DateDescription
2024-11-18Date of adoption of Rule 10b5-1 trading plan
2025-03-04Date of common stock acquisition and stock option grant
2025-03-06Date of common stock disposal
2035-03-04Expiration date of stock options

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.